Paul and Theodora return to TWiV to explain their research on determining the number of neutralizing epitopes on the SARS-CoV-2 spike that are recognized by antibodies, and engineering of a polymutant spike with twenty amino acid changes that demonstrates the high genetic barrier to escape from convalescent serum.
On this episode, TWiV makes Bloomberg Business News 2020 Jealousy List, crushing of CDC revealed by insiders, seasonal influenza during the COVID-19 pandemic, FDA briefing documents from Moderna, and three-quarters attack rate of SARS-CoV-2 during an unmitigated epidemic in Brazil.
Daniel Griffin provides a clinical report on COVID-19, and Shane Crotty explains a study of antibodies, B cells and T cells in patients which suggests that immunological memory to SARS-CoV-2 might be long-lived.
Daniel Griffin provides a clinical report on COVID-19, including vaccines, Alan summarizes a vaccine webinar on the most advanced US trials, a nidovirus from snapping turtles, longevity of memory B cells in recovered patients, and listener email.
Immunologist Shane Crotty joins TWiV to discuss the antibody and T cell responses to infection with SARS-CoV-2, followed by answers to listener questions.
Vincent, Rich, and Brianne discuss a study estimating the fraction of symptoms and severe disease after SARS- CoV-2 infection, cellular immune responses without seroconversion during interfamilial infections, and answer listener email.
Jon Yewdell returns to explain studies on detection of antibodies and T cell epitopes in patients who have recovered from COVID-19.
The TWiV team summarizes serology-based tests for SARS-CoV-2, lack of effect of ACE inhibitors or ARBs on COVID-19 severity, and answers listener questions.
Daniel Griffin provides his weekly update on the COVID-19 clinical situation, followed by our discussion of tests of an inactivated vaccine, results of serological surveys, an inhibitor of the cell protease needed for virus entry, and answers to listener questions.
Stanley Perlman joins TWiV to discuss immune responses to coronaviruses, including seasonal CoV, MERS, SARS, and SARS-CoV-2, including prospects for a vaccine.